OKYO · Company research
OKYO Pharma Limited Ordinary Shares (OKYO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada | H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment By Investing.com Investing.com Canada | View source ↗ | Investing.com Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment - Investing.com | H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment Investing.com | View source ↗ | Investing.com | Oct 7, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain - The Globe and Mail | OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. - Stock Titan | First patients enroll in OKYO Pharma (OKYO)'s 12-week trial for eye pain. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. - Stock Titan | A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. - Stock Titan | A planned trial for corneal nerve pain will enroll about 111 people; OKYO's CEO presents Oct. 8. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Limited (NASDAQ: OKYO) Share Price, OKYO Stock News, OKYO Share Price & Updates - Kalkine | OKYO Pharma Limited (NASDAQ: OKYO) Share Price, OKYO Stock News, OKYO Share Price & Updates Kalkine | View source ↗ | Kalkine | Sep 4, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - Simply Wall Street | OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans Simply Wall Street | View source ↗ | Simply Wall Street | Jul 27, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative | OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 23, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Announces Purchase of Shares by Director - Yahoo Finance | OKYO Pharma Announces Purchase of Shares by Director Yahoo Finance | View source ↗ | Yahoo Finance | Jul 23, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Announces Purchase of Shares by Chairman - Yahoo Finance | OKYO Pharma Announces Purchase of Shares by Chairman Yahoo Finance | View source ↗ | Yahoo Finance | Jul 22, 2026 | neutral | 0 | 0.6 |
| OKYO Forecast — Price Target — Prediction for 2027 - TradingView | OKYO Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jul 11, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain - Yahoo Finance | OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
| OKYO Pharma Announces Chairman and Founder Acquires Shares - Yahoo Finance | OKYO Pharma Announces Chairman and Founder Acquires Shares Yahoo Finance | View source ↗ | Yahoo Finance | Mar 19, 2026 | neutral | 0 | 0.6 |
| 7 Best Stocks Under $5 That Experts Are Buying Now 2026 - Intellectia AI | 7 Best Stocks Under $5 That Experts Are Buying Now 2026 Intellectia AI | View source ↗ | Intellectia AI | Feb 3, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 25, 2024 | neutral | 0 | 0.6 |
| OKYO Pharma: OKYO Stock Price Quote & News - Robinhood | OKYO Pharma: OKYO Stock Price Quote & News Robinhood | View source ↗ | Robinhood | Mar 18, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.